Underlying lung disease and exposure to terrestrial moderate and high altitude: personalised risk assessment

BMC Pulm Med. 2022 May 9;22(1):187. doi: 10.1186/s12890-022-01979-z.

Abstract

Once reserved for the fittest, worldwide altitude travel has become increasingly accessible for ageing and less fit people. As a result, more and more individuals with varying degrees of respiratory conditions wish to travel to altitude destinations. Exposure to a hypobaric hypoxic environment at altitude challenges the human body and leads to a series of physiological adaptive mechanisms. These changes, as well as general altitude related risks have been well described in healthy individuals. However, limited data are available on the risks faced by patients with pre-existing lung disease. A comprehensive literature search was conducted. First, we aimed in this review to evaluate health risks of moderate and high terrestrial altitude travel by patients with pre-existing lung disease, including chronic obstructive pulmonary disease, sleep apnoea syndrome, asthma, bullous or cystic lung disease, pulmonary hypertension and interstitial lung disease. Second, we seek to summarise for each underlying lung disease, a personalized pre-travel assessment as well as measures to prevent, monitor and mitigate worsening of underlying respiratory disease during travel.

Keywords: Air travel; Chronic lung disease; Exercise performance; High altitude travel; Hypoxic tests; Prediction tools.

Publication types

  • Review

MeSH terms

  • Altitude
  • Altitude Sickness* / prevention & control
  • Humans
  • Hypoxia
  • Lung Diseases, Interstitial*
  • Risk Assessment